Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT) (TIMEPOINT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04105335
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : January 27, 2020
Sponsor:
Information provided by (Responsible Party):
Mina Alpha Limited

Brief Summary:

This is an open label Phase 1a/1b study in patients who have advanced solid cancer tumours. Patients will receive MTL-CEBPA (an experimental drug) in combination with pembrolizumab (a drug which has been given approval for use for some tumour types).

The Phase 1a dose escalation part of the study is designed to establish which doses of MTL-CEBPA are safe and well-tolerated when combined with the standard dose of pembrolizumab. Patients recruited to this part of the study will be those whose cancer progressed on standard treatment(s) or for whom no treatments are available.

Phase 1b the dose expansion part of the study will further explore how safe and well-tolerated these two drugs are when combined and will assess if the combination of drugs could potentially reduce the size of tumours. Participants in this part of the study will receive the experimental drug (MTL-CEBPA) at a dose which is considered safe and well-tolerated based on data from the first part of the study (Phase 1a). Participants will remain in the study taking study drugs until either death, or they choose to withdraw from the study.


Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Drug: MTL-CEBPA Drug: Pembrolizumab Phase 1

Detailed Description:

Phase 1a comprises three planned dose cohorts (ascending dose, 3+3 design, at the following dose levels: 70 mg/m2 QW, 98 mg/m2 QW, and 130 mg/m2 QW) of MTL-CEBPA combined with standard dose of pembrolizumab (given every 3 weeks). The aim is to assess the safety and tolerability of MTL-CEBPA in combination with pembrolizumab, recruiting patients whose disease progressed on standard of care therapy or for whom no therapy is available.

In the first dose cohort the first participant enrolled will receive MTL-CEBPA treatment at the 70mg/m2 QW dose level. Pembrolizumab (200mg) will be administered on Day 2 of the first cycle and subsequently every 3 weeks whilst participant is on treatment. MTL-CEBPA and pembrolizumab will not be administered on the same day.

Phase 1b of the study will further evaluate safety, tolerability, and assess the clinical activity of MTL-CEBPA and a PD-1 inhibitor (pembrolizumab) in combination.

Participants will receive MTL-CEBPA at a dose considered most appropriate, with regards to safety, tolerability, and efficacy, for further development (based on data from Phase 1a of the study).

Patients with the following (but not limited to) solid tumours will be specifically targeted: breast, lung, ovarian, pancreatic, gall bladder, HCC, neuroendocrine, and cholangiocarcinoma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

The principal objective of the first part of the study (Phase 1a) is to establish if a combination of an experimental drug (MTL-CEBPA) with pembrolizumab (PD-1 inhibitor) is safe and well-tolerated in patients with advanced solid tumours.

Phase 1b will aim to confirm the doses of the drugs obtained in Phase 1a in a larger population and if it has potential to reduce the size of the tumour and/or extend the life of participants.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase 1a/b Study of MTL-CEBPA in Combination With a PD-1 Inhibitor (Pembrolizumab) in Adult Patients With Advanced Solid Tumours
Actual Study Start Date : November 13, 2019
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : June 30, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort 1 MTL-CEBPA in combination with pembrolizumab
MTL-CEBPA 70mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
Drug: MTL-CEBPA
Intravenous administration

Drug: Pembrolizumab
Intravenous administration
Other Name: Keytruda

Experimental: Cohort 2 MTL-CEBPA in combination with pembrolizumab
MTL-CEBPA 98mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
Drug: MTL-CEBPA
Intravenous administration

Drug: Pembrolizumab
Intravenous administration
Other Name: Keytruda

Experimental: Cohort 3 MTL-CEBPA in combination with pembrolizumab
MTL-CEBPA 130mg/m2 administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
Drug: MTL-CEBPA
Intravenous administration

Drug: Pembrolizumab
Intravenous administration
Other Name: Keytruda

Experimental: Expansion Cohort MTL-CEBPA in combination with pembrolizumab
MTL-CEBPA RP2D administered weekly over 3 weeks followed by 1 week of rest combined with pembrolizumab 200mg administered every 3 weeks.
Drug: MTL-CEBPA
Intravenous administration

Drug: Pembrolizumab
Intravenous administration
Other Name: Keytruda




Primary Outcome Measures :
  1. Adverse events [ Time Frame: From screening visit through study completion, an average of 1 year ]
    Frequency of adverse events graded according to toxicity criteria (NCI CTCAE v 5.0) and categorised by body system and diagnosis.

  2. Anti-tumour activity [ Time Frame: information on how the event is determined and over what estimated period of time (e.g., "From date of sceening visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months ]
    Change from baseline CT scan using the revised Response Evaluation Criteria in Solid Tumours (RECIST) guideline version 1.1 modified RECIST(mRECIST) and irRECIST


Secondary Outcome Measures :
  1. Pharmokinetic analysis of the study drug MTL-CEBPA when co administered with pembrolizumab [ Time Frame: Blood samples will be collected on Days 1, 2, 3, 4, 8, 9 10, and 11 of the study ]
    Blood sampling Blood samples collected at pre-defined timepoints will be analysed to define the maximum plasma concentration (Cmax) of MTL-CEBPA after intravenous administration.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed diagnosis of any solid tumour
  • Patients with progressive disease, refractory to standard of care with no standard therapy available or patient refused standard therapy
  • Patients who are naïve to PD-1 / PD-L1 inhibitors
  • ECOG PS 0 - 1
  • Life expectancy greater than 3 months at the time of recruitment
  • At least one measurable tumour lesion with target lesion size ≥ 1.0 cm as measured by CT
  • Negative blood pregnancy test for women of childbearing potential (within 10 days prior to first drug administration)
  • For women who are of child-bearing potential (see definition below) agreement to remain abstinent or use single or combined contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least three months after the last dose of MTL-CEBPA or four months after the last dose of pembrolizumab, whichever is longer.
  • Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal occlusion, male sterilization, hormone implants, established/proper use of combined oral or injected hormonal contraceptives and certain intrauterine devices. Alternatively, two methods (e.g., two barrier methods such as a condom and a cervical cap) may be combined to achieve a failure rate < 1% per year. Barrier methods must always be supplemented with the use of a spermicide.
  • Male participants with partners of child-bearing potential are required to use barrier contraception plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for at least three months after the last dose of MTL-CEBPA or four months after the last dose of pembrolizumab, whichever is longer. Male participants will also be advised to abstain from sexual intercourse with pregnant or lactating women, or to use condoms.
  • Abstinence is only acceptable if it is line with the preferred and usual lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods), declaration of abstinence for the duration of exposure to IMP, and withdrawal are not acceptable methods of contraception.
  • Note: a woman is considered of child-bearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent methods of sterilization include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy. A post-menopausal state is defined as no menses for 12 months without an alternative medical cause.
  • Able to comply with all the requirements of the protocol

Exclusion Criteria:

  • Patients who received investigational drug(s) including vaccines within the last 30 days prior to study treatment initiation (Cycle 1 Day 1)
  • Grade > 1 prior treatment-related toxicity (excluding alopaecia) at the time of screening
  • Cancer ascites related to liver failure on physical examination
  • Patients with history of haemorrhage or gastrointestinal perforation
  • Patients with history of bilateral portal vein occlusion
  • Known infection with human immunodeficiency virus (HIV)
  • Patients with known history of infection with hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known infection with hepatitis C (defined as detectable HCV RNA via qualitative nucleic acid testing)
  • Patients with central nervous system (CNS) or peritoneal metastasis
  • Patients with known history of non-infectious pneumonitis, myocarditis, or nephritis
  • Patients presenting with a marked baseline prolongation of QT/QTc interval defined as repeated demonstration of a QTc interval≥ 450ms (males) and ≥ 460ms (females) using Fridericia's correction formula.
  • Signs and symptoms of heart failure characterised as greater than New York Heart Association (NYHA) Class I or other clinically significant cardiac abnormalities (such as myocardial infarction) including stable abnormalities.
  • Major surgery within the last 30 days prior to study treatment initiation
  • Patients with history of solid organ or haematological transplantation
  • Patients with sepsis, ineffective biliary drainage with or without cholangitis, obstructive jaundice or encephalopathy at screening visit or within the last two weeks prior to study treatment initiation, whichever is earlier
  • Evidence of spontaneous bacterial peritonitis or renal failure, or allergic reaction at screening visit or within the last two weeks prior to study treatment initiation, whichever is earlier
  • Pregnant or lactating women
  • Received systemic corticosteroids and other immunosuppressants in the 4 weeks prior to enrolment into the study (please note exceptions detailed in Prohibited medication section).
  • Received live (attenuated) vaccine in the 30 days prior to first dose of study drug.
  • Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease] requiring immunosuppressive treatment, diverticulitis [with the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this criterion:
  • Patients with vitiligo or alopecia.
  • Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement.
  • Any chronic skin condition that does not require systemic therapy.
  • Patients without active disease in the last 2 years may be included but only after consultation with the study physician.
  • Patients with coeliac disease controlled by diet alone.
  • Patients with an active infection requiring systemic therapy.
  • Known hypersensitivity to the active substance (pembrolizumab) or to any of the excipients.
  • Known hypersensitivity to the active substance (MTL-CEBPA) or to any of the excipients.
  • Any other condition (e.g., known or suspected poor compliance, etc.) that, in the judgment of the investigator, may affect the participant's ability to follow the protocol specific procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04105335


Contacts
Layout table for location contacts
Contact: MiNA Alpha Limited +44 (0)20 8811 6764 timepoint@minatx.com
Contact: Ruth Plummer, FMedSci +44 (0)191 213 8444 ruth.plummer@newcastle.ac.uk

Locations
Layout table for location information
United Kingdom
Imperial College Healthcare NHS Trust Recruiting
London, United Kingdom, W12 0HS
Sponsors and Collaborators
Mina Alpha Limited
Investigators
Layout table for investigator information
Study Director: Nagy Habib, ChM, FRCS Mina Alpha Limited

Additional Information:
Layout table for additonal information
Responsible Party: Mina Alpha Limited
ClinicalTrials.gov Identifier: NCT04105335    
Other Study ID Numbers: MNA-3521-012
2019-002231-28 ( EudraCT Number )
First Posted: September 26, 2019    Key Record Dates
Last Update Posted: January 27, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Mina Alpha Limited:
Oligonucleotide
saRNA
Pembrolizumab
Tumour microenvironment
Myeloid-derived suppressor cells
C/EBP-a
CEBPA
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents